TRVI Insider Trading

Insider Ownership Percentage: 24.37%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $897,979.71

Trevi Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Trevi Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$549ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Trevi Therapeutics Share Price & Price History

Current Price: $6.75
Price Change: Price Increase of +0.46 (7.31%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for TRVI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$6.75Closing price on 03/14/25:

SEC Filings (Institutional Ownership Changes) for Trevi Therapeutics (NASDAQ:TRVI)

95.76% of Trevi Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TRVI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$137Mbought$22MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Trevi Therapeutics logo
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Read More on Trevi Therapeutics

Today's Range

Now: $6.75
Low: $6.28
High: $6.78

50 Day Range

MA: $4.35
Low: $3.56
High: $6.75

52 Week Range

Now: $6.75
Low: $2.30
High: $7.39

Volume

1,915,221 shs

Average Volume

2,023,841 shs

Market Capitalization

$518.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Who are the company insiders with the largest holdings of Trevi Therapeutics?

Trevi Therapeutics' top insider investors include:
  1. David P Meeker (Director)
  2. Thomas Sciascia (Insider)
  3. Jennifer L Good (CEO)
  4. Farrell Simon (Insider)
  5. Lisa Delfini (CFO)
Learn More about top insider investors at Trevi Therapeutics.

Who are the major institutional investors of Trevi Therapeutics?

Trevi Therapeutics' top institutional shareholders include:
  1. Frazier Life Sciences Management L.P. — 13.87%
  2. Point72 Asset Management L.P. — 5.40%
  3. Vivo Capital LLC — 4.54%
  4. Woodline Partners LP — 4.18%
  5. MPM Bioimpact LLC — 4.03%
  6. Adage Capital Partners GP L.L.C. — 3.25%
Learn More about top institutional investors of Trevi Therapeutics stock.

Which major investors are selling Trevi Therapeutics stock?

In the last quarter, TRVI stock was sold by these institutional investors:
  1. VR Adviser LLC
  2. Ally Bridge Group NY LLC
  3. Landscape Capital Management L.L.C.
  4. Tejara Capital Ltd
  5. Marshall Wace LLP
  6. Algert Global LLC
  7. Bridgeway Capital Management LLC
  8. Citadel Advisors LLC
During the last year, company insiders that have sold Trevi Therapeutics company stock include:
  1. David P Meeker (Director)
  2. Thomas Sciascia (Insider)
  3. Jennifer L Good (CEO)
  4. Farrell Simon (Insider)
  5. Lisa Delfini (CFO)
Learn More investors selling Trevi Therapeutics stock.

Which major investors are buying Trevi Therapeutics stock?

Within the last quarter, TRVI stock was purchased by institutional investors including:
  1. Point72 Asset Management L.P.
  2. Frazier Life Sciences Management L.P.
  3. Woodline Partners LP
  4. Adage Capital Partners GP L.L.C.
  5. Acorn Capital Advisors LLC
  6. Vivo Capital LLC
  7. MPM Bioimpact LLC
  8. Acuta Capital Partners LLC